Union Budget 2026-27's Biopharma SHAKTI Initiative: A 10,000-Crore Game-Changer
Finance Minister Nirmala Sitharaman's Union Budget 2026-27 has unveiled a transformative 10,000-crore Biopharma SHAKTI initiative spanning five years, marking a decisive policy shift toward advanced biologics and biosimilars. This strategic move signals India's ambition to evolve from a volume-driven generics manufacturer to an innovation-led global biopharma hub.
Industry Leaders Hail a Turning Point
Dr Krishna Ella, executive chairman of Bharat Biotech, described the scheme as "a turning point" that enables India to move decisively from volume-based manufacturing to high-value, innovation-led healthcare. "With the 10,000 crore commitment to building an ecosystem for biologics and biosimilars, the government is enabling India to move decisively from volume-based manufacturing to high-value, innovation-led healthcare," he stated.
Dr Ella further emphasized the budget's forward-looking approach, noting its recognition of India's shifting disease profile and the need for advanced bio-pharma solutions.
Accelerating the Journey from Volume to Value
Satish Reddy, chairman of Dr Reddy's Laboratories, highlighted that the programme would be "a key enabler for India's journey from volume to value leadership," helping transform the country from a global supplier of quality medicines into a global innovator.
Dr K Anand Kumar, managing director of Indian Immunologicals, pointed out that India already supplies nearly 60% of the world's vaccines. He stressed that targeted investments in advanced manufacturing infrastructure, high-containment facilities, and indigenous production of key raw materials would strengthen supply-chain resilience and reinforce India's role as a global vaccine and biologics hub.
Addressing Clinical and Regulatory Bottlenecks
A major bottleneck for advanced therapies has been the time and capacity required for high-quality clinical studies. The budget proposal to create a network of 1,000 accredited clinical trial sites is seen as a crucial step to make India more attractive for research and shorten domestic development timelines.
Regulatory capacity also received significant attention, with plans to strengthen the Central Drugs Standard Control Organisation through a dedicated scientific review cadre. Shreehas Tambe, CEO and managing director of Biocon Biologics, called this "a vital measure" to align India with global benchmarks in quality, speed, and scientific rigour.
Global Alignment and Talent Development
Winselow Tucker, president and general manager of Eli Lilly India, noted that globally aligned regulations and expanded clinical research would help bring innovation to patients faster and cement India's standing as a trusted life-sciences hub.
Additionally, the establishment of new NIPERs and upgrades to existing ones will expand advanced scientific education and build the talent pipeline necessary for innovation-led growth, as highlighted by industry stakeholders.
A Strategic Shift in Healthcare Policy
This biopharma push, combined with the Centre's earlier 1 lakh crore commitment to research, development, and innovation, represents a comprehensive strategy to accelerate India's transition from scale-led generics to innovation-led development and complex manufacturing. The Biopharma SHAKTI initiative underscores a sharper policy focus on science-based regulation and advanced therapeutic solutions, positioning India to compete effectively in the global biopharmaceutical landscape.
